Tirzepatide vs DSIP
A comprehensive, data-driven comparison of Tirzepatide (Mounjaro) and DSIP (Delta Sleep-Inducing Peptide). Compare efficacy, side effects, costs, FDA approval status, and clinical evidence to make an informed decision.
Side-by-Side Comparison
| Property | Tirzepatide Mounjaro, Zepbound | DSIP Delta Sleep-Inducing Peptide |
|---|---|---|
| FDA Status | FDA Approved | Category 2 |
| Category | Weight Loss | Sleep |
| Primary Use | Type 2 diabetes, chronic weight management, and obstructive sleep apnea | Sleep disorders and stress reduction |
| Weight Loss % | 22.5% | N/A |
| Monthly Cost | $1,100 - $1,100/mo | $35 - $70/mo |
| Administration | Subcutaneous injection | Subcutaneous injection |
| Typical Dose | 15mg weekly (max dose) | 100-300mcg before bed |
| Frequency | Weekly | Daily |
| Mechanism | Dual GIP/GLP-1 receptor agonist that enhances insulin secretion, reduces glucagon, slows gastric emptying, and decreases appetite | Neuropeptide that may modulate sleep patterns, reduce stress, and regulate circadian rhythms |
| Common Side Effects |
|
|
| Serious Side Effects |
|
|
| Evidence Quality | High | Emerging |
| Clinical Trial Phase | Approved | N/A |
Key Differences
- 1Tirzepatide is FDA-approved, while DSIP is currently category 2.
- 2Tirzepatide has clinical weight loss data (22.5%), while DSIP is not primarily indicated for weight loss.
- 3DSIP is generally more affordable ($35 - $70/mo) compared to Tirzepatide ($1,100 - $1,100/mo).
- 4Tirzepatide is dosed weekly, while DSIP is daily.
- 5Tirzepatide has high-quality evidence, while DSIP has emerging-quality evidence.
- 6They belong to different categories: Tirzepatide (Weight Loss) vs DSIP (Sleep).
Which Is Better For...
Tirzepatide
Those seeking an FDA-approved treatment with established safety data
DSIP
More budget-friendly option with lower monthly costs
Tirzepatide
More convenient dosing schedule (weekly)
DSIP
Fewer commonly reported side effects
Tirzepatide
Stronger clinical evidence base to support its use
Cost Comparison
| Peptide | Monthly Cost Range | FDA Status | Manufacturer |
|---|---|---|---|
| Tirzepatide | $1,100 - $1,100/mo | FDA Approved | Eli Lilly |
| DSIP | $35 - $70/mo | Category 2 | Various research labs |
Prices are estimated monthly costs and may vary based on pharmacy, insurance coverage, and manufacturer assistance programs. Costs for non-FDA-approved peptides reflect research compound pricing.
Frequently Asked Questions
Tirzepatide works via Dual GIP/GLP-1 receptor agonist that enhances insulin secretion, reduces glucagon, slows gastric. DSIP works via Neuropeptide that may modulate sleep patterns, reduce stress, and regulate circadian rhythms. They differ in FDA approval status, efficacy data, and cost.
Tirzepatide has demonstrated 22.5% average weight loss in clinical trials. DSIP is not primarily used for weight loss.
Tirzepatide typically costs $1,100 - $1,100/mo, while DSIP costs $35 - $70/mo. Prices may vary by pharmacy, insurance coverage, and manufacturer programs.
Tirzepatide is FDA-approved. DSIP is not FDA-approved (Category 2). FDA approval indicates the treatment has met rigorous safety and efficacy standards.
Common side effects of Tirzepatide include Nausea, Diarrhea, Decreased appetite. Common side effects of DSIP include Injection site reactions, Drowsiness, Vivid dreams. Always consult a healthcare provider about potential side effects.
Switching between peptide therapies should only be done under the guidance of a qualified healthcare provider. They can evaluate your medical history, current response, and determine the safest transition protocol.
Learn More
Tirzepatide is a dual-action peptide approved by the FDA as Mounjaro for type 2 diabetes and Zepbound for weight management. In December 2024, Zepbound became the first and only medication approved fo...
View Full Tirzepatide GuideDSIP (Delta Sleep-Inducing Peptide) is a neuropeptide first discovered in 1977 in the brains of sleeping rabbits. Research suggests it may have broader effects on stress response, pain modulation, and...
View Full DSIP GuideOther Popular Comparisons
Medical Disclaimer
The information provided on this page is for educational and informational purposes only and does not constitute medical advice. This comparison between Tirzepatide and DSIP should not be used as a substitute for professional medical guidance. Always consult a qualified healthcare provider before starting, stopping, or modifying any peptide therapy. Clinical data cited may be from ongoing trials and is subject to change. Individual results may vary significantly. PeptideVS does not endorse, recommend, or promote the use of any specific peptide for medical treatment.